Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Free Cash Flow (2016 - 2025)

Tvardi Therapeutics' Free Cash Flow history spans 13 years, with the latest figure at -$5.7 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 17.63% to -$5.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$23.5 million, a 21.44% decrease, with the full-year FY2025 number at -$23.5 million, down 21.44% from a year prior.
  • Free Cash Flow hit -$5.7 million in Q4 2025 for Tvardi Therapeutics, down from -$4.3 million in the prior quarter.
  • Over the last five years, Free Cash Flow for TVRD hit a ceiling of $23.4 million in Q2 2024 and a floor of -$34.6 million in Q1 2023.
  • Historically, Free Cash Flow has averaged -$13.8 million across 5 years, with a median of -$16.5 million in 2021.
  • Biggest five-year swings in Free Cash Flow: plummeted 1788.35% in 2022 and later skyrocketed 214.58% in 2024.
  • Tracing TVRD's Free Cash Flow over 5 years: stood at -$1.2 million in 2021, then plummeted by 1788.35% to -$23.5 million in 2022, then increased by 19.45% to -$18.9 million in 2023, then soared by 74.48% to -$4.8 million in 2024, then dropped by 17.63% to -$5.7 million in 2025.
  • Business Quant data shows Free Cash Flow for TVRD at -$5.7 million in Q4 2025, -$4.3 million in Q3 2025, and -$8.9 million in Q2 2025.